



Senior Services News

*A Newsletter Published by the
N.J. Department of Human Services
Division of Aging Services*

Volume 26 No. 02

December 2023

TO: Hospitals, Physicians, Advanced Practice Nurses, Midwives, Independent Clinics, Providers of Pharmaceutical Services – **For Action**
Managed Care Organizations – **For Information**

SUBJECT: **GlaxoSmithKline (GSK) and Eli Lilly withdrawal from the New Jersey Pharmaceutical Assistance to the Aged and Disabled (PAAD) and Senior Gold prescription assistance programs**

EFFECTIVE: January 1, 2024

PURPOSE: To notify prescribers and providers of pharmaceutical services of upcoming changes to drug coverage for PAAD and Senior Gold beneficiaries.

BACKGROUND: GSK and Eli Lilly have terminated their rebate agreements with the PAAD and Senior Gold prescription assistance programs. Under state law, drug products can only be covered by PAAD and Senior Gold if the manufacturer participates in the rebate program. As a result, the PAAD and Senior Gold programs can no longer assist with copays for GSK or Eli Lilly products, with the exception of insulin, effective **January 1, 2024**.

ACTION: The PAAD and Senior Gold programs can no longer assist with copays for GSK or Eli Lilly products, with the exception of insulin, effective January 1, 2024. Examples of these products are listed below.

GSK Products

Advair	Anoro Ellipta	Arnuity Ellipta	Beconase AQ	Breo Ellipta
Coreg	Flolan	Flovent	Imitrex	Incruse Ellipta
Jalyn	Jemperli	Krintafel	Lamictal	Malarone
Mepron	Nucala	Rythmol SR	Relenza	Serevent Diskus
Trelegy Ellipta	Valtrex	Ventolin HFA	Wellbutrin SR	Zejula

Eli Lilly Products

Alimta	Amyvid	Baqsimi	Cialis	Cymbalta
Cyramza	Emgality	Evista	Forteo	Glucagon
Humatrope	Jaypirca	Mounjaro	Olumiant	Portrazza
Prozac	Retevmo	Reyvow	Strattera	Symbyax
Taltz	Tauvid	Trulicity	Verzenio	Zyprexa

This change means the PAAD and Senior Gold programs will discontinue coverage of all non-insulin drugs manufactured under the following labeler codes.

Labeler Code	Labeler Name
00173	GlaxoSmithKline LLC
00007	GlaxoSmithKline LLC
00002	Eli Lilly & Co.
00777	Dista Labs

Drugs under the above Labeler codes will receive the following rejection code:
REJECT CODE = 570 – Drug Not Payable – No State Rebate Agreement (NCPDP REJECT CODE = AC)

PAAD and Senior Gold beneficiaries have been notified that these products will no longer be covered by PAAD/Senior Gold as of January 1, 2024. If they continue to utilize GSK or Eli Lilly products after that date, they will be responsible for the full copay or cost of the medication. Additional copay assistance may be possible by requesting a tier reduction from their primary insurance plan or by contacting the manufacturer patient assistance program. To learn more about the GSK program, visit [GSKforYou.com](https://www.gskforyou.com) or call 1-866-GSK-FOR-U (1-866-475-3678). To learn more about the Eli Lilly program, visit www.lillycares.com or call 1-800-545-6962.

If there are any questions regarding this Newsletter, please contact the PAAD program at 1-800-792-9745.

RETAIN THIS NEWSLETTER FOR REFERENCE